On the lag phase in amyloid fibril formation.

Arosio P, Knowles TP, Linse S. · 2015

Read On the lag phase in amyloid fibril formation. by Arosio P, Knowles TP, Linse S. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4498454.txt.

Introduction

Paolo Arosio, Tuomas Knowles, and Sara Linse examined the lag phase of amyloid fibril formation in Physical Chemistry Chemical Physics in 2015. Amyloid fibrils, highly ordered protein fibers, are linked to more than thirty human diseases, including Alzheimer's, Parkinson's, and diabetes, most of them incurable. Before fibers grow visibly, a solution of single protein molecules sits apparently idle for a lag period whose microscopic events decide the pace of the whole process.

The authors model and measure the rates of the invisible early steps for the Alzheimer's peptide A beta 42, starting from a dilute solution of single molecules. Tiny clusters must form, convert, and reach a size from which fibers can elongate. Their framework connects those hidden rates to the fibril growth curves experiments actually record. Understanding the lag phase matters because the early clusters are thought to be the most toxic species and the best targets for drugs.

Catalog record

CREATORArosio P, Knowles TP, Linse S.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4498454

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

On the lag phase in amyloid fibril formation By Paolo Arosio, Tuomas P. J. Knowles, Sara Linse Published in: Physical Chemistry Chemical Physics DOI: 10.1039/c4cp05563b ABSTRACT Rates of microscopic processes taking place during the lag phase of amyloid fibril formation for a reaction starting from an initially monomeric 4 μm solution of Aβ42. INTRODUCTION Amyloid fibrils are observed in connection with more than 30 human diseases that are increasingly prevalent yet currently incurable in the vast majority of cases. Well-known examples are Amyloid Lateral Sclerosis (ALS), Alzheimer, Parkinson, Huntington's diseases and diabetes.1–4 Amyloid has also emerged as a functional state in bacteria and fungi,5 as well as in humans.6–8 Such functionality is thought to originate from the fact that this stage offers a route towards the very tight packing of proteins, which provides a stable storage environment, favorable mechanical properties and in some cases an active catalytic surface for biosynthetic pathways.9 From an ultra-structural point of view, amyloid fibrils are highly ordered and elongated aggregates characterized at the molecular level by the presence of an array of β-strands oriented perpendicularly to the long axis of the fiber.10–12 Despite great variation in sequence length and native, or natively unfolded, structure of the precursor proteins, once assembled into amyloid fibrils, they possess highly similar generic structures but with some variation in local packing leading to morphological differences in, for example, twist and internal lateral packing of β sheets (Fig. 1). [Figure: Sketches of amyloid forming proteins associated to several human diseases.] Thus, the amyloid structure is likely to represent an alternative stable structure for peptides and proteins accessible to most if not all peptides and proteins.13,14 An individual amyloid fibril is often formed from a protein with a given core sequence and the structure is highly repetitive with the same inter-protein contacts stabilizing the strands throughout the length of the fibril.10,11 Amyloid deposits found in vivo in the context of disease may, however, contain more than one protein, or protein variant, a fact that may be due to association of fibrils or association of other proteins to the fibrils.15 Amyloid deposits can also be rich in lipids.16 For many amyloid-forming proteins, it has been found that monomers and full-length fibrils induce limited or no toxicity to neurons or other cells.17 In contrast, cell death can be induced by smaller aggregates of intermediate sizes forming during the amyloid growth process.18,19 The size-distribution and structures of these toxic assemblies are not established, although some hints are emerging.20–23 It has also been proposed that the aggregation process per se is toxic.24 In all cases, cellular toxicity is associated with an ongoing assembly process in which free monomers are converted to the amyloid state. From a biological and biomedical point of view, it is therefore of key importance to understand the amyloid formation process in terms of the underlying molecular events that define its mechanism. Such a mechanistic understanding implies a dissection of the overall aggregation process into its underlying composite reactions, the microscopic steps. Moreover, important insights may be gained by defining the rate constants governing each microscopic step and determining the manner in which they depend on protein sequence as well as on solution conditions such as salt, pH, temperature, other proteins, membranes, and species that inhibit protein aggregation. One relevant feature of the aggregation process of amyloids is the lag-phase that is commonly observed during the kinetics of fibril formation. The molecular origin of this lag-phase has historically attracted large attention because of the key mechanistic information that is potentially contained in this macroscopic observable. In this review, after presenting the currently available experimental evidences, we discuss the microscopic mechanisms underlying the origin of the lag-phase, providing a mechanistic framework to dissect information on the microscopic aggregation steps from this measurable macroscopic phase. We elucidate most of the concepts discussed in this work using as an example the Alzheimer's disease-associated peptide Aβ42, for which a detailed quantitative and mechanistic picture of the aggregation process is now available. However, the concept of lag-phase discussed here is general, and applies to other amyloidogenic peptides and proteins. MONOMERS, AGGREGATES, FIBRILS, OLIGOMERS AND NUCLEI The species observed to form as a consequence of protein aggregation processes are commonly highly heterogeneous. Indeed, the overall reaction results in the conversion of monomeric soluble peptides or proteins into an array of aggregate structures; in large part due to this significant level of heterogeneity, a standard terminology to describe specific aggregate species has not yet emerged; in the following, a monomer is defined as a single protein or peptide chain. Monomers may exist free in solution or as complexes with other monomers in aggregates. With aggregate we denote any assembly containing more than one monomer, i.e. dimers, trimers and higher order assemblies. Amyloid fibrils are linear aggregates with a repetitive cross-beta structure which may consist of tens of thousands of monomers. These structures are able to elongate rapidly from their ends by association of peptides or proteins from the solution phase. By contrast, many smaller aggregates, commonly termed oligomers, elongate significantly more slowly than amyloid fibrils. The definitions for oligomers vary in the literature. This term is often used to refer to aggregates up to a certain size, e.g. 2–20-mers. Here, the upper limit is not always given, and different limits may be of practical value for different systems. The significantly lower rates of growth process for oligomers compared to amyloid fibrils suggest that there are significant structural differences between amyloid fibrils and oligomers. Indeed, among the several possible definitions, oligomers can be described as small aggregates exhibiting different structure and lower growth rate with respect to fibrils. It has been challenging, however, to define the smallest size of an aggregate that possesses the characteristics of an amyloid fibril rather than of an oligomer, since rapid elongation makes the shortest fibrils extremely short-lived and difficult to observe. In some reports, oligomers are defined according to preparation method, or in terms of which substances are added to block them from further growth. In this report we will use the term oligomer to define the small aggregates that are generated by the first few elongation events of nuclei without any reference to their structure. Nuclei are the smallest aggregates in the process that are stable enough that further growth by monomer addition is faster than dissociation into monomers. In energetic terms, nuclei are thus the species with highest Gibbs free energy (Fig. 2) along the aggregation pathway. We note that the schematic shown in Fig. 2 is only a simplified version of the complex multi-dimensional free energy diagram associated to the formation of amyloid fibrils. In addition, nucleation reactions follow complicated pathways that populate a cascade of intermolecular metastable species.25 [Figure: Free energy diagram of amyloid fibril formation. The nucleus is the state with the highest free energy. Fibrils and monomers may have similar free energy, and the total concentration of monomer governs which state dominates at equilibrium.] It is worth pointing out that in the figures of this work, monomeric units are illustrated as spheres without inference to their structures, because in the frame of the mechanistic models discussed in this paper energetic diagrams and reaction schemes are described in a coarse-grained

Read the complete text